研究单位：[1]Betta Pharmaceuticals Co.,Ltd.[2]Sichuan Cancer Hospital&Institute Chengdu,Sichuan,China,610042[3]The Sixth People's Hospital of Chengdu Chengdu,Sichuan,China,610051[4]Tianjin Cancer Hospital Tianjin,Tianjin,China,300181[5]Jiangsu Cancer Hospital Nanjing,Jiangsu,China,210009[6]The Second Affiliated Hospital of Soochow University Suzhou,Jiangsu,China,215004[7]Xuzhou Central Hospital Xuzhou,Jiangsu,China,221009[8]The First Affiliated Hospital of Gannan Medical College Ganzhou,Jiangxi,China,100044[9]The First Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China,330006[10]The Third Hospital of Nanchang Nanchang,Jiangxi,China,330008[11]Jilin Cancer Hospital Changchun,Jilin,China,130012
研究目的：
This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally advanced，recurrent or metastatic breast cancer with disease progression following endocrine therapy.
